文献速递胸部肿瘤放疗放疗物理与技术

低剂量全肺放疗治疗COVID-19患者与肺癌及心脏病风险的关联

Lung Cancer and Heart Disease Risks Associated With Low-Dose Pulmonary Radiotherapy to COVID-19 Patients With Different Background Risks.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-04-27

该研究基于美国辐射风险模型与背景风险数据,估算不同性别、50至85岁接受低剂量全肺放疗的COVID-19患者终生肺癌与主要冠脉事件风险。结果显示女性吸烟者50至60岁治疗时肺癌终生风险最高约6%,高心脏病风险因素者50至60岁治疗时心脏病风险最高约3%,高基线风险患者合计终生风险可达9%。

要点

  • 女性吸烟者50至60岁接受低剂量全肺放疗,终生肺癌风险最高约6%。
  • 高心脏病风险因素者50至60岁治疗,终生主要冠脉事件风险最高约3%。
  • 高基线风险患者肺癌与心脏病合计终生风险可达9%。

核心结论

  • 高基线风险因素患者低剂量全肺放疗后肺癌与主要冠脉事件合计终生风险可达9%。
  • 老年不吸烟且心脏风险因素少的患者预测风险最低。
  • 评估低剂量放疗获益风险时应考虑背景风险因素,尤其是吸烟。

研究设计与样本

  • 结合肺癌与心脏病最先进辐射风险模型、美国背景风险及年龄性别依赖生存概率进行估算。
  • 估算对象为不同性别、治疗年龄50至85岁、有或无吸烟及基线心脏病风险的COVID-19患者。

主要发现

  • 辐射所致绝对风险一般肺癌高于主要冠脉事件。
  • 女性吸烟者50至60岁治疗时终生肺癌风险最高约6%。
  • 高心脏病风险因素男性或女性50至60岁治疗时终生心脏病风险最高约3%。
  • 高基线风险因素患者合计终生风险可达9%。
  • 老年不吸烟且心脏风险因素少的患者预测风险最低。

临床怎么用

  • 评估低剂量全肺放疗治疗重症COVID-19肺部症状的获益风险平衡时可参考上述终生风险估算。
  • 此类评估中应考虑背景风险因素,尤其吸烟。
  • 还需结合可能急性反应综合考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The respiratory disease COVID-19 reached global pandemic status in 2020. Excessive inflammation is believed to result in the most severe symptoms and death from this disease. Because treatment options for patients with severe COVID-19 related pulmonary symptoms remain limited, whole-lung low-dose radiation therapy is being evaluated as an anti-inflammatory modality. However, there is concern about the long-term risks associated with low-dose pulmonary irradiation. To help quantify the benefit-risk balance of low-dose radiation therapy for COVID-19, we estimated radiation-induced lifetime risks of both lung cancer and heart disease (major coronary events) for patients of different sexes, treated at ages 50 to 85, with and without other relevant risk factors (cigarette smoking and baseline heart disease risk). METHODS AND MATERIALS: These estimates were generated by combining state-of-the-art radiation risk models for lung cancer and for heart disease together with background lung cancer and heart disease risks and age/sex-dependent survival probabilities for the U.S. RESULTS: Estimated absolute radiation-induced risks were generally higher for lung cancer compared with major coronary events. The highest estimated lifetime radiation-induced lung cancer risks were approximately 6% for female smokers treated between ages 50 and 60. The highest estimated radiation-induced heart disease risks were approximately 3% for males or females with high heart disease risk factors and treated between ages 50 and 60. CONCLUSIONS: The estimated summed lifetime risk of lung cancer and major coronary events reached up to 9% in patients with high baseline risk factors. Predicted lung cancer and heart disease risks were lowest in older nonsmoking patients and patients with few cardiac risk factors. These long-term risk estimates, along with consideration of possible acute reactions, should be useful in assessing the benefit-risk balance for low-dose radiation therapy to treat severe COVID-19 pulmonary symptoms, and suggest that background risk factors, particularly smoking, should be taken into account in such assessments.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Shuryak I, Kachnic LA, Brenner DJ, et al. Lung Cancer and Heart Disease Risks Associated With Low-Dose Pulmonary Radiotherapy to COVID-19 Patients With Different Background Risks. Int J Radiat Oncol Biol Phys. 2021. PMID: 33930480. doi:10.1016/j.ijrobp.2021.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。